Clinical Trials Logo

Clinical Trial Summary

Haemorrhagic stroke, an emergency caused by bleeding in the brain, often leads to death or long-term disability. A quarter of these patients are taking blood-thinning drugs (antiplatelet drugs, such as aspirin) because they are at risk of a heart attack or ischaemic stroke. Patients taking these drugs are more likely to die or be disabled if they have a haemorrhagic stroke. At present, there is no effective treatment for reversing their effects. Desmopressin is a drug which may reverse the effects of antiplatelet drugs and stop bleeding. The investigators would like to run a large randomised trial to see if Desmopressin can reduce the number of people who die or are disabled after haemorrhagic stroke.

Clinical Trial Description

Intracerebral haemorrhage is a medical emergency, caused by a blood vessel bleeding directly into the brain. Outcome is directly related to the amount of bleeding that occurs. Many patients die early and others are left with significant disability. A quarter of all people with intracerebral haemorrhage are taking an antiplatelet drug, which is associated with larger volumes of brain haemorrhage and significantly worse outcomes. Four to five million people are taking antiplatelet drugs in the UK and use continues to rise in an ageing population.

Despite advances in treatment of ischaemic stroke, there is no effective drug treatment for intracerebral haemorrhage. Treatment for intracerebral haemorrhage has been identified as a priority area by Stroke Association and stroke survivors.

Desmopressin is a drug that reverses blood thinning effects of antiplatelet drugs, by indirectly increasing platelet adhesion, which the investigators hypothesise will minimise the devastating consequences of intracerebral haemorrhage associated with antiplatelet drugs. Desmopressin is commonly used in patients with inherited platelet dysfunction disorders and is an appealing treatment for antiplatelet-associated intracerebral haemorrhage. A recent systematic review did not find any randomised controlled trials evaluating desmopressin for antiplatelet-associated intracerebral haemorrhage. Desmopressin is affordable, available and could be implemented clinically across the UK and worldwide in the next five years with immediate benefit for stroke patients, their families and society. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03696121
Study type Interventional
Source University of Nottingham
Contact Diane Havard
Phone +44 115 8231775
Status Recruiting
Phase Phase 2
Start date April 1, 2019
Completion date June 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Recruiting NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Recruiting NCT03633422 - Evaluation of Stroke Patient Screening
Not yet recruiting NCT03843008 - Melatonin in Acute Stroke N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Recruiting NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Completed NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Recruiting NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT03618290 - Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke
Recruiting NCT03235271 - Pilot Study of Acute Stroke Using the Brainpulseâ„¢
Completed NCT03634748 - Thrombolysis in stRoke With Unknown onSet Based on noncontrasT CT
Completed NCT03324321 - Feasibility of Improving Cerebral Autoregulation in Acute Intracerebral Haemorrhage N/A
Recruiting NCT03495206 - Safety, Tolerability and Pharmacokinetics of Y-2(Adaravone And Borneol) Sublingual Tablet Phase 1
Not yet recruiting NCT03641963 - aICP Measurement in Patients With Cerebral Artery Infarction / aICP MCA Infarction N/A